Animace načítání

Stránka se připravuje...


Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

NAŘÍZENÍ XXXXXX X&xxxx;XXXXXXXXX XXXXXXXXX (EU) 2022/692

xx xxx 16.&xxxx;xxxxx 2022,

xxxxxx xx xxx účely xxxxxxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxxx xxxx nařízení Xxxxxxxxxx xxxxxxxxxx a Rady (ES) x.&xxxx;1272/2008 o klasifikaci, xxxxxxxxxx x&xxxx;xxxxxx xxxxx a směsí

(Text x&xxxx;xxxxxxxx xxx EHP)

EVROPSKÁ XXXXXX,

x&xxxx;xxxxxxx na Xxxxxxx x&xxxx;xxxxxxxxx Xxxxxxxx unie,

s ohledem xx nařízení Xxxxxxxxxx xxxxxxxxxx a Rady (ES) x.&xxxx;1272/2008 xx dne 16.&xxxx;xxxxxxxx&xxxx;2008 o klasifikaci, označování x&xxxx;xxxxxx xxxxx x&xxxx;xxxxx, x&xxxx;xxxxx a zrušení xxxxxxx 67/548/XXX x&xxxx;1999/45/XX x&xxxx;x&xxxx;xxxxx xxxxxxxx (XX) x.&xxxx;1907/2006&xxxx;(1), x&xxxx;xxxxxxx xx čl. 37 xxxx.&xxxx;5 uvedeného xxxxxxxx,

xxxxxxxx x&xxxx;xxxxx xxxxxxx:

(1)

Xxxxxxx 3 x&xxxx;xxxxx 3 xxxxxxx XX nařízení (ES) x.&xxxx;1272/2008 xxxxxxxx xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx x&xxxx;xxxxxxxx xxxxxxxxxxxx xxxxx na xxxxxxx xxxxxxxx stanovených x&xxxx;xxxxxxx 2 xx 5 xxxxxxx X&xxxx;xxxxxxxxx xxxxxxxx.

(2)

Xxxxxxxx xxxxxxxx xxx xxxxxxxx látky (dále xxx „agentura“) xxxx x&xxxx;xxxxxxx x&xxxx;xxxxxxx&xxxx;37 xxxxxxxx (XX) x.&xxxx;1272/2008 xxxxxxxxxx xxxxxx na zavedení xxxxxxxxxxxxx klasifikace a označení xxxxxxxxx xxxxx a na xxxxxxxxxxx nebo zrušení xxxxxxxxxxxxxxx klasifikací a označení xxxxxxxxx xxxxxx xxxxx. Xxxx, xx Xxxxx xxx posuzování rizik (XXX) xxxxxxxx xxxxxxxxx xxxxxxxxxx zúčastněných xxxxx, xxxxxx k těmto xxxxxxx xxxxxxxxxxx stanoviska (2):

—

stanovisko xx xxx 5.&xxxx;xxxxxxxx&xxxx;2019 xxx xxxxxxxxx, 1,1,1-xxxxxxxxx-X-(xxxxxxxxxxxxxx)-, xxxxxxxx xxxxxxxxx s oxidem xxxxxxxxxx; xxxxxxxxx xxxxxxxxxx xxxxxxx xxxx křemičitý v nanoformě x&xxxx;xxxxxxxxxx úpravou,

—

stanovisko ze xxx 4.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxxx (ISO), [(3-xxxxxx-4-xxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 4.&xxxx;xxxxxx&xxxx;2020 xxx β-cyfluthrin (ISO); xxxxxxx xxxx: xxx-(X)-xxxx(4-xxxxx-3-xxxxxxxxxxx)xxxxxx-(1X,3X)-3-(2,2-xxxxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx x&xxxx;xxx-(X)-xxxx(4-xxxxx-3-xxxxxxxxxxx)xxxxxx- (1S,3R)-3-(2,2-dichlorethenyl)-2,2-dimethylcyklopropan-1-karboxylát,

—

stanovisko ze xxx 4. května 2020 xxx xxxxxxxxxxx (XXX); (1X)-X-[(6-xxxxxxxxxxxx-3-xx)xxxxxx]-X’-xxxx-X-xxxxxxxxxxxxxxxxxxx; (X)-X 1-[(6-chlor-3-pyridyl)methyl]-N 2-kyan-N 1-xxxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze dne 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxx,

—

xxxxxxxxxx xx dne 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxx xxxxxxxxxxx,

—

xxxxxxxxxx xx dne 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxxxxxxx 2,2-dimethylpropan-1-olu; 3-xxxx-2,2-xxx(xxxxxxxxxx)xxxxxx-1-xx,

—

xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxxxxxxxxx (XXX); 5-{[2-(2-butoxyethoxy)ethoxy]methyl}-6-propyl-1,3-benzodioxol,

—

stanovisko ze xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx xxx-1,7,7-xxxxxxxxxxxxxxxx[2.2.1]xxxx-2-xx-xxxxxxx; xxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxx (XXX); 4-(2,2-xxxxxxxxxxxxxxxxx)-4-xxxxxxxxxxxx kyselinu; X-(xxxxxxxxxxxxx)xxxxxxxxxxxx xxxxxxxx,

—

xxxxxxxxxx xx xxx 11. června 2020 pro xxxxxxxxxxx (XXX); 3,6-xxx(x-xxxxxxxxxx)-1,2,4,5-xxxxxxxx,

—

xxxxxxxxxx xx xxx 11. června 2020 xxx fluopikolid (ISO); 2,6-xxxxxxx-X-[3-xxxxx-5-(xxxxxxxxxxxxxx)-2-xxxxxxx]xxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 11. června 2020 xxx 2-xxxxxxxxxxxxxx xxxxxxxx x&xxxx;xxxx xxxx,

—

xxxxxxxxxx ze xxx 11.&xxxx;xxxxxx&xxxx;2020 xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx {[(xxxxxxxxxxxxx)xxxxx]xxx(xxxxxxxxxxxxxx)}xxxxxxxxxxx xxxxxxxx x&xxxx;xxxxxx xxxxxxxxxxxx x&xxxx;xxxxxxxxxxxxxxx xxxx xx xxxxxx Xxxxxxxx xxxxxx,

—

xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx xxxxxxxxxx-xxx(2-xxxxxxxxxxxxx),

—

xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx dibutylcín-diacetát,

—

stanovisko xx dne 17.&xxxx;xxxx&xxxx;2020 xxx xxxxxxxxx xxxxxxx-xxxxxxxx,

—

xxxxxxxxxx xx dne 17.&xxxx;xxxx&xxxx;2020 xxx chinoklamin (XXX); 2-xxxxx-3-xxxxx-1,4-xxxxxxxxxxx,

—

xxxxxxxxxx xx dne 17.&xxxx;xxxx&xxxx;2020 xxx 4,4’-xxxxx(xxxxxxxxxxxxxxxxxxxxx),

—

xxxxxxxxxx xx dne 17. září 2020 xxx xxxxxx-4-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 17. září 2020 pro xxxxxxxxx; 1,3-xxxxxxxx-3,7-xxxxxxx-1X-xxxxx-2,6-xxxx,

—

xxxxxxxxxx ze xxx 17.&xxxx;xxxx&xxxx;2020 pro 1,3-xxx(1-xxxxxxxxxx-1-xxxxxxxxxxx)xxxxxx; [x-XXXXX],

—

xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx 1,3-xxx(xxxxxxxxxxxxxxxx)xxxxxx; [x-XXX],

—

xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx 2,4,6-xxxxxxxxxxxx-x-xxxxxxx-xxxxxxxxxxx,

—

xxxxxxxxxx ze dne 17.&xxxx;xxxx&xxxx;2020 pro triamid xxxxxxxx N-(2-nitrofenyl)fosforečné,

—

stanovisko xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx xxxxx,

—

xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx 2-ethyl-2-{[(1-oxoallyl)oxy]methyl}propan-1,3-diyl-diakrylát; 2,2-xxx(xxxxxxxxxxxxxxxxx)xxxxx-xxxxxxx; xxxxxxxxxxxxxxxxx-xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx 1,5-xxxxxxxxxxxxxxxxxxxx [obsahující &xx;&xxxx;0,1&xxxx;% xxxx. částic x&xxxx;xxxxxxxxxxxxxx xxxxxxxx menším xxx 50 μx],

—

xxxxxxxxxx ze xxx 17.&xxxx;xxxx&xxxx;2020 pro 1,5-xxxxxxxxxxxxxxxxxxxx [xxxxxxxxxx ≥&xxxx;0,1&xxxx;% xxxx. xxxxxx s aerodynamickým xxxxxxxx xxxxxx xxx 50 μm],

—

stanovisko ze xxx 8. října 2020 xxx xxxxxx xxxxxx,

—

xxxxxxxxxx ze xxx 8. října 2020 pro 2,4,6-xxx-xxxx-xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8.&xxxx;xxxxx&xxxx;2020 xxx pyridalyl (XXX); 2,6-xxxxxxx-4-(3,3-xxxxxxxxxxxxxxx)xxxxx{3-[5-(xxxxxxxxxxxxxx)-2-xxxxxxxxxx]xxxxxx}xxxxx,

—

xxxxxxxxxx xx xxx 8.&xxxx;xxxxx&xxxx;2020 pro xxxxxxx-2-xxxxx-1-xxxx, sodnou xxx; xxxxxx xxx xxxxxxxxxx; xxxxxxxxx sodný,

—

stanovisko xx xxx 8. října 2020 xxx X-(5-xxxxx-2-xxxxxxxxxxxxxxx)-X-xxxxxxxxxxx-3-(xxxxxxxxxxxxx)-5-xxxxx-1-xxxxxx-1X-xxxxxxx-4-xxxxxxxxxx; isoflucypram,

—

stanovisko ze xxx 8.&xxxx;xxxxx&xxxx;2020 xxx 2-(2-xxxxxxxxxxxxx)xxxxxxx; diethylenglykolmonomethylether,

—

stanovisko xx xxx 8.&xxxx;xxxxx&xxxx;2020 pro 4,4′-xxxxxxxxxxxxxxxxxxxx; xxxxxxxx X,

—

xxxxxxxxxx xx xxx 8. října 2020 xxx pendimethalin (XXX); X-(1-xxxxxxxxxxx)-2,6-xxxxxxx-3,4-xxxxxxx,

—

xxxxxxxxxx ze dne 8.&xxxx;xxxxx&xxxx;2020 xxx dimoxystrobin (XXX); (2X)-2-{2-[(2,5-xxxxxxxxxxxxxx)xxxxxx]xxxxx}-2-(xxxxxxxxxxxx)-X-xxxxxxxxxxxxxx; (X)-2-(xxxxxxxxxxxx)-X-xxxxxx-2-[α-(2,5-xxxxxxxx)-x-xxxxx]xxxxxxxx,

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx 4,4’-sulfonyldifenol; bisfenol X,

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx 2-{X-xxxxx-4-[(5-xxxxxxxxxxxx-2-xx)xxx]-x-xxxxxxxxx}xxxxx-xxxxxx; X.X. Xxxxxxxx Xxxx 124,

—

xxxxxxxxxx ze dne 10.&xxxx;xxxxxxxx&xxxx;2020 xxx kyselinu xxxxxxxxxxxxxxxxxx; xxxxxxxx xxxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx xxxxxx-X-(xxxxxxxxxxxxxxxxxx)-X-xxxxx-(3XX)-3-(4-xxxxxxxxxx)-β-xxxxxxxx; xxxxxxxxxxx,

—

xxxxxxxxxx xx dne 10. prosince 2020 xxx 6-[xxxxx-(X12-X18, xxxxxxxxxx, xxxxxxxxxx)-2,5-xxxxxxxxxxxxxxx-1-xx]xxxxxxxxx kyselinu, xxxxx x&xxxx;xxxx(2-xxxxxxxxxxxx)xxxxxx xxxx,

—

xxxxxxxxxx ze xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx 6-[xxxxx-(X10-X13, rozvětvené, nenasycené)-2,5-dioxopyrrolidin-1-yl]hexanovou xxxxxxxx,

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 pro 6-[alkyl-(C12-C18, xxxxxxxxxx, nenasycené)-2,5-dioxopyrrolidin-1-yl]hexanovou kyselinu,

—

stanovisko xx dne 10.&xxxx;xxxxxxxx&xxxx;2020 xxx 1,3,5-xxxxxxx-2,4,6-xxxxxxx; melamin,

—

stanovisko xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx reakční xxxx: 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-[(1XX,4XX,9XX)-1,2,3,4-xxxxxxxxxx-9-xxxxxxxxx-1,4-xxxxxxxxxxxxxxx-5-xx]xxxxxxx-4-xxxxxxxxxx x&xxxx;3-(xxxxxxxxxxxxx)-1-xxxxxx-X-[(1XX,4XX,9XX)-1,2,3,4-xxxxxxxxxx-9-xxxxxxxxx-1,4-xxxxxxxxxxxxxxx-5-xx]xxxxxxx-4-xxxxxxxxxx [xxxxxxxxx xxxxx ≥&xxxx;78&xxxx;% xxx-xxxxxxx x&xxxx;≤&xxxx;15&xxxx;% xxxx-xxxxxxx], xxxxxxxxxx,

—

xxxxxxxxxx xx dne 10.&xxxx;xxxxxxxx&xxxx;2020 xxxxxxx xxxxxxx, extraktu [x&xxxx;xxxxx xxxxxxxx Azadirachta xxxxxx, xxxxxxxxxxx vodou x&xxxx;xxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx],

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 pro xxxx xxxxxxxxx,

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 pro xxxxxxxx (XXX), 3-xxxxxxxxx-2,1,3-xxxxxxxxxxxxxxx-4-xx-2,2-xxxxxx,

—

xxxxxxxxxx xx xxx 10. prosince 2020 xxxxxxx xxxxxxxxxx xxxxxxxxx nových xxxxxxxxx x&xxxx;xxxxxx inhalační xxxxxxxx 2-xxxxxxxxxxx-1-xxx; xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx (XXXX) xx xxxxxx Xxxxxxxx xxxxxx.

(3)

Xxxx xxxxxxxx xxxxxxxxx xxxxxxxxx, xxxxx xxxxxxxxxxx xxxxxxx posouzení xxxxxxx xx xxxxxxxxxxxx XXX xx dne 11.&xxxx;xxxxxx&xxxx;2020 xxx 2-xxxxxxxxxxxxxx xxxxxxxx a její xxxx; xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx {[(karboxymethyl)imino]bis(ethylennitrilo)}tetraoctové xxxxxxxx a jejích pentasodných x&xxxx;xxxxxxxxxxxxxxx xxxx xx xxxxxx Xxxxxxxx komise, xx dne 8. října 2020 xxx bromid xxxxxx, xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx xxxx vanadičný, xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxxxxxx opětovného xxxxxxxxx xxxxxx informací o akutní xxxxxxxxx toxicitě 2-xxxxxxxxxxx-1-xxx; xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx (XXXX) xx xxxxxx Xxxxxxxx xxxxxx x&xxxx;xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx xxxxxxx.

(4)

Xxxxxx tyto xxxxxxxxx xxxxxxxxx xxxxxxxxx x&xxxx;xxxxxxxxxx je xx xxxxxxxxxx x&xxxx;xxxx, aby xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxxxx xx xxxxxxxxxxxx XXX. Xx xxxxxxx xxxxxxxxx provedeného v uvedených xxxxxxxxxxxx xx xxxxx xxxxxx xxxxxx, aktualizovat xxxx zrušit xxxxxxxxxxxxxx xxxxxxxxxxx a označení dotčených xxxxx.

(5)

Xxxx, co bylo Xxxxxx xxxxxxx xxxxxxxxxx XXX, byly xxxxxxxx xxxxxxxxx informace týkající xx xxxxxx xxxxxxxxx xxxxxxxx silanaminu, 1,1,1-xxxxxxxxx-X-(xxxxxxxxxxxxxx)-, xxxxxxxx xxxxxxxxx x&xxxx;xxxxxx xxxxxxxxxx; xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxx x&xxxx;xxxxxxxxx x&xxxx;xxxxxxxxxx xxxxxxx. Xxxxxxxxxxx silanaminu, 1,1,1-xxxxxxxxx-X-(xxxxxxxxxxxxxx)-, xxxxxxxx hydrolýzy x&xxxx;xxxxxx xxxxxxxxxx; xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxx x&xxxx;xxxxxxxxx s povrchovou úpravou xxxx akutní inhalační xxxxxxxx kategorie 2, xxxxxxxxxx ve xxxxxxxxxx XXX ze dne 5.&xxxx;xxxxxxxx&xxxx;2019, xx xxxxxx xxx xxxxxxxx xx xxxxxxx VI xxxxxxxx (XX) č. 1272/2008, xxxxx Xxxxxx nové vědecké xxxxxxxxx xxxxxxxxx a neshledala, xx xx xxxx xxxxx xxxxx xxxxxxxxx XXX. Xx xxxxxxx XX xxxxxxxx (XX) x.&xxxx;1272/2008 xx xxxx xxxx xxx xxxxxxxx xxxxxxxxxxx xxxx xxxxx xxxx XXXX RE 2, doporučená ve xxxxxxxxxx xxxxxx RAC xx xxx 5.&xxxx;xxxxxxxx&xxxx;2019, xxxxx xxxxxx obdrženy xxxxx xxxx xxxxxxxxx, xxxxx by xxxxxxxxxx xxxxx xxxxxxxxx této xxxxxxxxxxx.

(6)

Xxxxxxxx (ES) x.&xxxx;1272/2008 xx xxxxx xxxx xxx xxxxxxxxxxxxx způsobem xxxxxxx.

(7)

Xxxxxxxxxx nových xxxx xxxxxxxxxxxxxxx harmonizovaných klasifikací xx nemělo xxx xxxxxxxxxx xxxxx, xxxxxxx xxxxxxxxxx xxxxxxxxx určitou xxxx xx xx, xxx přizpůsobili označování x&xxxx;xxxxxx xxxxx x&xxxx;xxxxx xxxxx xxxx aktualizovaným xxxxxxxxxxxx x&xxxx;xxxxxxx xxxxxxxxx xxxxxx, na xxxxx xx xxxxxxxx předchozí xxxxxxxxxxx xxxxxxxxx. Xxxx xxxx xx rovněž xxxxxxxx x&xxxx;xxxx, xxx xxxxxxxxxx xxxx xxxxxxxx xxxx přijmout xxxxxxxx xxxxx x&xxxx;xxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxx xxxxxxxxx, xxxxx vznikají x&xxxx;xxxxxxxx změn xxxxxxxxxxx xxxxx tohoto xxxxxxxx. Xxxxxxxxxxx xx však xxxx xxx umožněno xxxxxxxx xxxx xxxx xxxxxxxxxxxxx xxxxxxxxxxxxx klasifikace x&xxxx;xxxxxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxxx x&xxxx;xxxxxx na xxxxxxxxxxx xxxxxxx xxxx xxxxx použitelnosti xxxxxx xxxxxxxx, xxx xxxx xxxxxxxxx xxxxxx xxxxxx xxxxxxx lidského xxxxxx x&xxxx;xxxxxxxxx prostředí a aby xx xxxxxxxxxxx poskytla xxxxxxxxxx xxxxxxxx,

XXXXXXX XXXX XXXXXXXX:

Xxxxxx&xxxx;1

Xxxxx nařízení (XX) x.&xxxx;1272/2008

Xxxxxxx XX xxxxxxxx (XX) x.&xxxx;1272/2008 xx xxxx v souladu s přílohou xxxxxx nařízení.

Xxxxxx&xxxx;2

Xxxxx v platnost x&xxxx;xxxxxxxxxxxx

Xxxx xxxxxxxx vstupuje x&xxxx;xxxxxxxx xxxxxxxx dnem xx xxxxxxxxx x&xxxx;Xxxxxxx věstníku Xxxxxxxx xxxx.

Xxxxxxx xx xxx xxx 23.&xxxx;xxxxxxxxx 2023.

Xxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx článku xxxxx být xxxxx x&xxxx;xxxxx xxxxxxxxxxxxx, označovány x&xxxx;xxxxxx v souladu s tímto xxxxxxxxx xxx xxx xxxx xxxxxx x&xxxx;xxxxxxxx.

Xxxx xxxxxxxx xx xxxxxxx v celém rozsahu x&xxxx;xxxxx použitelné xx xxxxx členských xxxxxxx.

X&xxxx;Xxxxxxx xxx 16.&xxxx;xxxxx 2022.

Za Xxxxxx

xxxxxxxxxxx

Xxxxxx XXX DER XXXXX


(1)&xxxx;&xxxx;Xx. xxxx. X&xxxx;353, 31.12.2008, x.&xxxx;1.

(2)&xxxx;&xxxx;Xxxxxxxxxx jsou xxxxxxxx xx xxxx xxxxxxxxxxx xxxxxxx: https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/. – Xxxxxxxxxx ze xxx 11. června 2020 a ze xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxxxxxxx xx xxxxxxxxxx xxxxxxxxx xx xxxxxx Xxxxxxxx xxxxxx xxxx k dispozici xx xxxx xxxxxxxxxxx xxxxxxx: https://echa.europa.eu/about-us/who-we-are/committee-for-risk-assessment/opinions-of-the-rac-adopted-under-specific-echa-s-executive-director-requests


XXXXXXX

Xxxxxxx XX xxxxxxxx (XX) x.&xxxx;1272/2008 xx xxxx xxxxx:

1)

x&xxxx;xxxxx 3 xx xxxxxxx 3 xxxx takto:

a)

vkládají xx xxxx xxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. limity, multiplikační xxxxxxx x&xxxx;XXX

Xxxxxxxx

Xxxx tříd x&xxxx;xxxxxxxxx nebezpečnosti

Kódy xxxxxxxxxxxx xxx x&xxxx;xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx x&xxxx;xxxxxxxxxx slov

Kódy xxxxxxxxxxxx xxx o nebezpečnosti

Kódy xxxxx. standardních xxx x&xxxx;xxxxxxxxxxxxx

„014-052-00-7

xxxxxxxxx, 1,1,1-xxxxxxxxx-X-(xxxxxxxxxxxxxx)-, produkty xxxxxxxxx s oxidem xxxxxxxxxx; xxxxxxxxx xxxxxxxxxx amorfní xxxx xxxxxxxxx v nanoformě x&xxxx;xxxxxxxxxx xxxxxxx

272-697-1

68909-20-6

XXXX XX 2

X373 (plíce) (xxxxxxxxxx)

XXX08

Xxx

X373 (xxxxx) (vdechování)

EUH066“

„035-005-00-7

bromid xxxxxx

235-183-8

12124-97-9

Xxxx. 1X

Xxxx.

XXXX XX 3

XXXX XX 1

Xxx Irrit. 2

X360XX

X362

X336

X372 (xxxxxxx systém)

H319

GHS08

GHS07

Dgr

H360FD

H362

H336

H372 (xxxxxxx systém)

H319“

„050-032-00-4

dibutylcín-bis(2-ethylhexanoát)

220-481-2

2781-10-4

Muta. 2

Xxxx. 1X

XXXX RE 1

H341

H360FD

H372 (xxxxxxxx xxxxxx)

XXX08

Xxx

X341

X360XX

X372 (xxxxxxxx xxxxxx)“

„050-033-00-X

xxxxxxxxxx-xxxxxxxx

213-928-8

1067-33-0

Xxxx. 2

Repr. 1X

XXXX XX 1

X341

X360XX

X372 (imunitní xxxxxx)

XXX08

Xxx

X341

X360XX

X372 (xxxxxxxx systém)“

„052-001-00-0

tellur

236-813-4

13494-80-9

Repr. 1X

Xxxx.

X360Xx

X362

XXX08

Xxx

X360Xx

X362“

„052-002-00-6

xxxx telluričitý

231-193-1

7446-07-3

Repr. 1X

Xxxx.

X360Xx

X362

XXX08

Xxx

X360Xx

X362“

„056-005-00-3

xxxxxxxxx xxxxxxx-xxxxxxxx

237-222-4

13701-59-2

Xxxx. 1X

Xxxxx Xxx. 4

Xxxxx Xxx. 3

X360XX

X332

X301

XXX08

XXX06

Xxx

X360XX

X332

X301

xxxxxxxxx:

XXX&xxxx;= 1,5&xxxx;xx/x (xxxxx nebo xxxx)

xxxxxx:

XXX&xxxx;= 100 mg/kg TH“

„601-097-00-8

propylbenzen

203-132-9

103-65-1

Flam. Xxx. 3

Xxx. Xxx. 1

XXXX SE 3

Aquatic Xxxxxxx 2

X226

X304

X335

X411

XXX02

XXX08

XXX07

XXX09

Xxx

X226

X304

X335

X411“

„603-243-00-6

xxxxxxxxxxxxxx 2,2-xxxxxxxxxxxxxx-1-xxx; 3-xxxx-2,2-xxx(xxxxxxxxxx)xxxxxx-1-xx

253-057-0

36483-57-5; 1522-92-5

Xxxx. 1B

Muta. 2

X350

X341

XXX08

Xxx

X350

X341“

„604-096-00-0

xxxxxxxxxxxxxxxx (ISO); 5-{[2-(2-xxxxxxxxxxxx)xxxxxx]xxxxxx}-6-xxxxxx-1,3-xxxxxxxxxxx

200-076-7

51-03-6

XXXX XX 3

Xxx Irrit. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H335

H319

H400

H410

GHS07

GHS09

Wng

H335

H319

H410

EUH066

M = 1

X&xxxx;= 1“

„604-097-00-6

2,4,6-xxx-xxxx-xxxxxxxxxx

211-989-5

732-26-3

Xxxx. 1B

Acute Tox. 4

XXXX XX 2

Skin Xxxx. 1X

X360X

X302

X373 (xxxxx)

X317

XXX08

XXX07

Xxx

X360X

X302

X373 (xxxxx)

X317

xxxxxx:

XXX&xxxx;= 500&xxxx;xx/xx TH“

„604-098-00-1

4,4’-sulfonyldifenol; xxxxxxxx S

201-250-5

80-09-1

Repr. 1X

X360XX

XXX08

Xxx

X360XX“

„606-153-00-5

xxxxxxxxxx

204-337-6

119-61-9

Xxxx. 1X

X350

XXX08

Xxx

X350“

„606-154-00-0

xxxxxxxxxxx (ISO); 2-xxxxx-3-xxxxx-1,4-xxxxxxxxxxx

220-529-2

2797-51-5

Xxxx. 2

Xxxx. 2

Xxxxx Xxx. 4

XXXX RE 2

Xxx Xxxxx. 2

Xxxx Sens. 1&xxxx;X

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H351

H361d

H302

H373 (xxxxxx xxxx, xxxxxxx)

X319

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X361x

X302

X373 (krevní xxxx, ledviny)

H319

H317

H410

orální:

ATE = 500&xxxx;xx/xx XX

X&xxxx;= 10

X&xxxx;= 10“

„607-756-00-6

xxx-1,7,7-xxxxxxxxxxxxxxxx[2.2.1]xxxx-2-xx-xxxxxxx; xxxxxxxxx-xxxxxxx

227-561-6

5888-33-5

Xxxx Sens. 1 A

H317

GHS07

Wng

H317“

„607-757-00-1

daminozid (XXX); 4-(2,2-xxxxxxxxxxxxxxxxx)-4-xxxxxxxxxxx xxxxxxxx; X-(xxxxxxxxxxxxx)xxxxxxxxxxx xxxxxxxx

216-485-9

1596-84-5

Xxxx. 2

X351

XXX08

Xxx

X351“

„607-758-00-7

4,4′-xxxxx(xxxxxxxxxxxxxxxxxxxxx)

201-286-1

80-51-3

Xxxx-xxxxx. X

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X242

X400

X410

XXX02

XXX09

Xxx

X242

X410

X&xxxx;= 1

X&xxxx;= 1“

„607-759-00-2

xxxxxx-4-xxxxxxxxxxxxxxx

216-407-3

1576-35-8

Xxxx-xxxxx. X

X242

XXX02

Xxx

X242“

„607-760-00-8

2-{X-xxxxx-4-[(5-xxxxxxxxxxxx-2-xx)xxx]-x-xxxxxxxxx}xxxxx-xxxxxx; X.X. Xxxxxxxx Xxxx 124

239-203-6

15141-18-1

Xxxx Xxxx. 1&xxxx;X

X317

XXX07

Xxx

X317

Xxxx Xxxx. 1&xxxx;X; H317: X&xxxx;≥&xxxx;0,001&xxxx;%“

„607-761-00-3

xxxxxxxxxxxxxxxxx xxxxxxxx; tridekafluorheptanová xxxxxxxx

206-798-9

375-85-9

Xxxx. 1X

XXXX XX 1

X360X

X372 (xxxxx)

XXX08

Xxx

X360X

X372 (xxxxx)“

„607-762-00-9

xxxxxx-X-(xxxxxxxxxxxxxxxxxx)-X-xxxxx-(3XX)-3-(4-xxxxxxxxxx)-β-xxxxxxxx; xxxxxxxxxxx

-

283159-90-0

Xxxx. 2

Xxxxxxx Chronic 2

H351

H411

GHS08

GHS09

Wng

H351

H411“

„607-763-00-4

6-[alkyl-(C12-C18, xxxxxxxxxx, xxxxxxxxxx)-2,5-xxxxxxxxxxxxxxx-1-xx]xxxxxxxx xxxxxxxx, xxxxx x&xxxx;xxxx(2-xxxxxxxxxxxx)xxxxxx soli

-

-

Repr. 1X

Xxx Xxxxx. 2

X360XX

X319

XXX08

XXX07

Xxx

X360XX

X319“

„607-764-00-X

6-[xxxxx-(X10-X13, xxxxxxxxxx, xxxxxxxxxx)-2,5-xxxxxxxxxxxxxxx-1-xx]xxxxxxxx xxxxxxxx

-

2156592-54-8

Xxxx. 1X

Xxx Xxxxx. 2

X360XX

X319

XXX08

XXX07

Xxx

X360XX

X319“

„607-765-00-5

6-[xxxxx-(X12-X18, xxxxxxxxxx, nenasycené)-2,5-dioxopyrrolidin-1-yl]hexanová kyselina

-

-

Repr. 1X

X360XX

XXX08

Xxx

X360XX“

„613-341-00-0

xxxxxxxxxxx (XXX); 3,6-bis(o-chlorfenyl)-1,2,4,5-tetrazin

277-728-2

74115-24-5

Aquatic Xxxxxxx 1

X410

XXX09

Xxx

X410

X&xxxx;= 1“

„613-342-00-6

xxxxxxxxx; 1,3-xxxxxxxx-3,7-xxxxxxx-1X-xxxxx-2,6-xxxx

200-385-7

58-55-9

Xxxx. 1B

H360D

GHS08

Dgr

H360D“

„613-343-00-1

pyridalyl (ISO); 2,6-xxxxxxx-4-(3,3-xxxxxxxxxxxxxxx)xxxxx{3-[5-(xxxxxxxxxxxxxx)-2-xxxxxxxxxx]xxxxxx}xxxxx

-

179101-81-6

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X317

X400

X410

XXX07

XXX09

Xxx

X317

X410

X&xxxx;= 1 000

M = 100“

„613-344-00-7

xxxxxxx-2-xxxxx-1-xxxx, xxxxx xxx; xxxxx xxx xxxxxxxxxx; pyrithion xxxxx

223-296-5;

240-062-8

3811-73-2;

15922-78-8

Xxxxx Tox. 3

Xxxxx Xxx. 3

Xxxxx Xxx. 4

XXXX XX 1

Skin Xxxxx. 2

Xxx Irrit. 2

Xxxx Xxxx. 1

Aquatic Xxxxx 1

Xxxxxxx Chronic 2

X331

X311

X302

X372 (xxxxxxx xxxxxx)

X315

X319

X317

X400

X411

XXX06

XXX08

XXX09

Xxx

X331

X311

X302

X372 (xxxxxxx xxxxxx)

X315

X319

X317

X410

XXX070

xxxxxxxxx:

XXX&xxxx;= 0,5&xxxx;xx/x (xxxxx xxxx xxxx)

xxxxxxxx:

XXX&xxxx;= 790&xxxx;xx/xx XX

xxxxxx:

XXX&xxxx;= 500&xxxx;xx/xx XX

X&xxxx;= 100“

„613-345-00-2

1,3,5-xxxxxxx-2,4,6-xxxxxxx;

xxxxxxx

203-615-4

108-78-1

Xxxx. 2

XXXX XX 2

H351

H373 (močové xxxxx)

XXX08

Xxx

X351

X373 (xxxxxx cesty)“

„615-046-00-2

1,3-bis(1-isokyanato-1-methylethyl)benzen; [x-XXXXX]

220-474-4

2778-42-9

Xxxx. Xxxx. 1

Xxxx Xxxx. 1&xxxx;X

X334

X317

XXX08

Xxx

X334

X317“

„615-047-00-8

1,3-xxx(xxxxxxxxxxxxxxxx)xxxxxx; [m-XDI]

222-852-4

3634-83-1

Resp. Xxxx. 1

Skin Xxxx. 1&xxxx;X

X334

X317

XXX08

Xxx

X334

X317

Xxxx Xxxx. 1&xxxx;X; X317: X&xxxx;≥&xxxx;0,001&xxxx;%“

„615-048-00-3

2,4,6-xxxxxxxxxxxx-x-xxxxxxx-xxxxxxxxxxx

218-485-4

2162-73-4

Xxxx. Sens. 1

Xxxx Xxxx. 1

X334

X317

XXX08

Xxx

X334

X317“

„615-049-00-9

1,5-xxxxxxxxxxxxxxxxxxxx

[xxxxxxxxxx &xx;&xxxx;0,1&xxxx;% xxxx. xxxxxx x&xxxx;xxxxxxxxxxxxxx xxxxxxxx menším xxx 50 μm]

221-641-4

3173-72-6

STOT XX 3

Xxxx Irrit. 2

Xxx Irrit. 2

Resp. Xxxx. 1

Xxxx Xxxx. 1&xxxx;X

Xxxxxxx Xxxxxxx 3

H335

H315

H319

H334

H317

H412

GHS07

GHS08

Dgr

H335

H315

H319

H334

H317

H412“

„615-050-00-4

1,5-diisokyanatonaftalen

[obsahující &xx;&xxxx;0,1&xxxx;% xxxx. částic x&xxxx;xxxxxxxxxxxxxx xxxxxxxx menším xxx 50 μx]

221-641-4

3173-72-6

Xxxxx Xxx. 2

STOT SE 3

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Resp. Xxxx. 1

Xxxx Xxxx. 1&xxxx;X

Xxxxxxx Xxxxxxx 3

X330

X335

X315

X319

X334

X317

X412

XXX06

XXX08

Xxx

X330

X335

X315

X319

X334

X317

X412

xxxxxxxxx:

XXX&xxxx;= 0,27 mg/l (xxxxx xxxx xxxx)“

„616-237-00-3

xxxxxxxxxxx (XXX); 2,6-xxxxxxx-X-[3-xxxxx-5-(xxxxxxxxxxxxxx)-2-xxxxxxx]xxxxxxxxxxxxxx

-

239110-15-7

Xxxx. 2

X361x

XXX08

Xxx

X361x“

„616-238-00-9

xxxxxxx xxxxxxxx N-(2-nitrofenyl)fosforečné

477-690-9

874819-71-3

Repr. 1X

XXXX XX 2

X360Xx

X373 (xxxxxxx)

XXX08

Xxx

X360Xx

X373 (xxxxxxx)“

„616-239-00-4

X-(5-xxxxx-2-xxxxxxxxxxxxxxx)-X-xxxxxxxxxxx-3-(xxxxxxxxxxxxx)-5-xxxxx-1-xxxxxx-1X-xxxxxxx-4-xxxxxxxxxx; xxxxxxxxxxxx

-

1255734-28-1

Xxxx. 2

Acute Xxx. 4

Skin Sens. 1X

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X361x

X332

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X317

X410

xxxxxxxxx:

XXX&xxxx;= 2,2 mg/l (xxxxx xxxx xxxx)

X&xxxx;= 10

X&xxxx;= 1“

„616-240-00-X

reakční směs: 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-[(1XX,4XX,9XX)-1,2,3,4-xxxxxxxxxx-9-xxxxxxxxx-1,4-xxxxxxxxxxxxxxx-5-xx]xxxxxxx-4-xxxxxxxxxx x&xxxx;3-(xxxxxxxxxxxxx)-1-xxxxxx-X-[(1XX,4XX,9XX)-1,2,3,4-xxxxxxxxxx-9-xxxxxxxxx-1,4-xxxxxxxxxxxxxxx-5-xx]xxxxxxx-4-xxxxxxxxxx [xxxxxxxxx xxxxx ≥&xxxx;78&xxxx;% xxx-xxxxxxx x&xxxx;≤&xxxx;15&xxxx;% xxxx-xxxxxxx], isopyrazam

-

881685-58-1

Carc. 2

Xxxx. 1B

Skin Sens. 1X

Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1

H351

H360D

H317

H400

H410

GHS08

GHS07

GHS09

Dgr

H351

H360D

H317

H410

Repr. 1X; X360X:

X&xxxx;≥&xxxx;3&xxxx;%

X&xxxx;= 10

X&xxxx;= 10“

„650-058-00-1

Xxxxxxx, extrakt [x&xxxx;xxxxx xxxxxxxx Azadirachta xxxxxx, xxxxxxxxxxx vodou x&xxxx;xxxx xxxxxxxxxx organickými rozpouštědly]

283-644-7

84696-25-3

Repr. 2

Xxxx Xxxx. 1

Aquatic Xxxxxxx 1

X361x

X317

X410

XXX08

XXX07

XXX09

Xxx

X361x

X317

X410

X&xxxx;= 10“

x)

xxxxxxx xxxxxxxxxxxx indexovým xxxxxx 014-001-00-9; 023-001-00-8; 601-024-00-X; 603-014-00-0; 603-107-00-6; 604-030-00-0; 607-111-00-9; 607-230-00-6; 607-253-00-1; 607-254-00-7; 607-734-00-6; 607-735-00-1; 607-736-00-7; 608-032-00-2; 609-042-00-X; 613-012-00-1; 616-164-00-7 xx xxxxxxxxx xxxxxx xxxxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx název

Číslo XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. limity, xxxxxxxxxxxxx faktory x&xxxx;XXX

Xxxxxxxx

Xxxx xxxx x&xxxx;xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx x&xxxx;xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx x&xxxx;xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx xxx x&xxxx;xxxxxxxxxxxxx

Xxxx doplň. xxxxxxxxxxxx xxx x&xxxx;xxxxxxxxxxxxx

„014-001-00-9

xxxxxxxxxxxxx

233-042-5

10025-78-2

Xxxx. Xxx. 1

Xxxxx-xxxxx. 1

Xxxxx Xxx. 3

Xxxxx Xxx. 4

Xxxx Xxxx. 1&xxxx;X

Xxx Xxx. 1

X224

X260

X331

X302

X314

X318

XXX02

XXX06

XXX05

Xxx

X224

X260

X331

X302

X314

XXX014

XXX029

XXX071

xxxxxxxxx:

XXX&xxxx;= 7,6&xxxx;xx/x (xxxx)

xxxxxx:

XXX&xxxx;= 1&xxxx;000 &xxxx;xx/xx TH“

„023-001-00-8

oxid xxxxxxxxx

215-239-8

1314-62-1

Xxxx. 2

Xxxx. 1X

Xxxx. 2

Xxxx.

Xxxxx Tox. 3

Xxxxx Xxx. 2

XXXX XX 3

XXXX XX 1

Xxxxxxx Xxxxxxx 2

X341

X350

X361xx

X362

X301

X330

X335

X372 (xxxxxxx xxxxx, vdechování)

H411

GHS06

GHS08

GHS09

Dgr

H341

H350

H361fd

H362

H301

H330

H335

H372 (xxxxxxx xxxxx, vdechování)

H411

inhalační:

ATE = 0,05&xxxx;xx/x (xxxxx xxxx xxxx)

xxxxxx:

XXX&xxxx;= 220&xxxx;xx/xx XX“

„601-024-00-X

xxxxx

202-704-5

98-82-8

Xxxx. Xxx. 3

Xxxx. 1X

Xxx. Tox. 1

XXXX XX 3

Xxxxxxx Xxxxxxx 2

X226

X350

X304

X335

X411

XXX02

XXX08

XXX07

XXX09

Xxx

X226

X350

X304

X335

X411“

„603-014-00-0

2-xxxxxxxxxxx-1-xx; xxxxxxxxxxxxx-xxxxxxxxx-xxxxx

203-905-0

111-76-2

Xxxxx Xxx. 3

Xxxxx Xxx. 4

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

X331

X302

X315

X319

XXX06

Xxx

X331

X302

X315

X319

xxxxxxxxx:

XXX&xxxx;= 3&xxxx;xx/x (xxxx)

xxxxxx:

XXX&xxxx;= 1 200  mg/kg XX“

„603-107-00-6

2-(2-xxxxxxxxxxxxx)xxxxxxx; diethylenglykolmonomethylether

203-906-6

111-77-3

Repr. 1X

X360X

XXX08

Xxx

X360X

Xxxx. 1X; H360D: C ≥ 3 %“

„604-030-00-0

4,4′-isopropylidendifenol; xxxxxxxx A

201-245-8

80-05-7

Repr. 1X

XXXX XX 3

Xxx Xxx. 1

Xxxx Xxxx. 1

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360X

X335

X318

X317

X400

X410

XXX08

XXX07

XXX05

XXX09

Xxx

X360X

X335

X318

X317

X410

X&xxxx;= 1

X&xxxx;= 10“

„607-111-00-9

2-ethyl-2-{[(1-oxoallyl)oxy]methyl}propan-1,3-diyl-diakrylát; 2,2-xxx(xxxxxxxxxxxxxxxxx)xxxxx-xxxxxxx;

xxxxxxxxxxxxxxxxx-xxxxxxxxxx

239-701-3

15625-89-5

Xxxx. 2

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X351

X315

X319

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X315

X319

X317

X410

X&xxxx;= 1

X&xxxx;= 1

D“

„607-230-00-6

2-ethylhexanová xxxxxxxx x&xxxx;xxxx xxxx, s výjimkou xxxx, xxxxx jsou xxxxxxx xxxxx v této xxxxxxx

-

-

Xxxx. 1B

H360D

GHS08

Dgr

H360D“

„607-253-00-1

cyfluthrin (XXX); [(3-xxxxxx-4-xxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx

269-855-7

68359-37-5

Xxxx.

Xxxxx Xxx. 2

Acute Xxx. 2

XXXX XX 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H362

H330

H300

H370 (xxxxxxx xxxxxx)

X400

X410

XXX06

XXX08

XXX09

Xxx

X362

X330

X300

X370 (xxxxxxx xxxxxx)

X410

xxxxxxxxx:

XXX&xxxx;= 0,14&xxxx;xx/x (xxxxx xxxx xxxx)

xxxxxx:

XXX&xxxx;= 14 mg/kg XX

X&xxxx;= 1&xxxx;000&xxxx;000

X&xxxx;= 1 000 000 “

„607-254-00-7

β-xxxxxxxxxx (XXX); xxxxxxx xxxx: xxx-(X)-xxxx(4-xxxxx-3-xxxxxxxxxxx)xxxxxx-(1X,3X)-3-(2,2-xxxxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx x&xxxx;xxx-(X)-xxxx(4-xxxxx-3-xxxxxxxxxxx)xxxxxx-(1X,3X)-3-(2,2-xxxxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx

-

1820573-27-0

Xxxx.

Xxxxx Xxx. 2

Xxxxx Xxx. 2

XXXX XX 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X362

X330

X300

X370 (xxxxxxx systém)

H400

H410

GHS06

GHS08

GHS09

Dgr

H362

H330

H300

H370 (nervový xxxxxx)

X410

xxxxxxxxx:

XXX&xxxx;= 0,081&xxxx;xx/x (xxxxx xxxx mlha)

orální:

ATE = 11&xxxx;xx/xx XX

X&xxxx;= 1&xxxx;000&xxxx;000

X&xxxx;= 1&xxxx;000&xxxx;000 “

„607-734-00-6

xxxxxxxxxxx-2,2‘,2“,2“‘,2“&xxxx;“ -(xxxxx-1,2-xxxxxxxxxxx)xxxxxxxxxxx

404-290-3

7216-95-7

Xxxx. 1B

Acute Xxx. 4

XXXX XX 2

Xxx Xxxxx. 2

X360X

X332

X373 (xxxxxxxxxx)

X319

XXX08

XXX07

Xxx

X360X

X332

X373 (xxxxxxxxxx)

X319

Xxxx. 1X; X360X: X&xxxx;≥&xxxx;3&xxxx;%

xxxxxxxxx:

XXX&xxxx;= 1,5&xxxx;xx/x (xxxxx xxxx mlha)“

„607-735-00-1

{[(karboxymethyl)imino]bis(ethylennitrilo)}tetraoctová xxxxxxxx

200-652-8

67-43-6

Xxxx. 1B

Acute Xxx. 4

XXXX RE 2

Eye Xxxxx. 2

X360X

X332

X373 (xxxxxxxxxx)

X319

XXX08

XXX07

Xxx

X360X

X332

X373 (xxxxxxxxxx)

X319

Xxxx. 1B; X360X: X&xxxx;≥&xxxx;3&xxxx;%

xxxxxxxxx:

XXX&xxxx;= 1,5&xxxx;xx/x (xxxxx xxxx xxxx)“

„607-736-00-7

xxxxxxxxxxxx-[(xxxxxxxxxxxxxxxxx)xxxxxxxx(xxxxxxxxxxxxxx)xxxxxxxxxxx]

205-391-3

140-01-2

Xxxx. 1X

Xxxxx Xxx. 4

XXXX RE 2

X360X

X332

X373 (vdechování)

GHS08

GHS07

Dgr

H360D

H332

H373 (xxxxxxxxxx)

Xxxx. 1X; H360D: X&xxxx;≥&xxxx;3&xxxx;%

xxxxxxxxx:

XXX&xxxx;= 1,5&xxxx;xx/x (xxxxx xxxx xxxx)“

„608-032-00-2

xxxxxxxxxxx (XXX); (1X)-X-[(6-xxxxxxxxxxxx-3-xx)xxxxxx]-X’-xxxx-X-xxxxxxxxxxxxxxxxxxx; (X)-X 1-[(6-chlor-3-pyridyl)methyl]-N 2-xxxx-X 1-xxxxxxxxxxxxxxxx

-

135410-20-7&xxxx;160430-64-8

Xxxx. 2

Xxxxx Xxx. 3

Xxxxxxx Xxxxxxx 1

Xxxxxxx Xxxxx 1

X361x

X301

X410

X400

XXX08

XXX06

XXX09

Xxx

X361x

X301

X410

xxxxxx:

XXX&xxxx;= 140 mg/kg XX

X&xxxx;= 10

X&xxxx;= 10“

„609-042-00-X

pendimethalin (XXX); X-(1-xxxxxxxxxxx)-2,6-xxxxxxx-3,4-xxxxxxx

254-938-2

40487-42-1

Xxxx. 2

Aquatic Xxxxx 1

Aquatic Xxxxxxx 1

X361x

X400

X410

XXX08

XXX09

Xxx

X361x

X410

X&xxxx;= 100

X&xxxx;= 10“

„613-012-00-1

xxxxxxxx (XXX); 3-xxxxxxxxx-1X-2,1,3-xxxxxxxxxxxxxxx-4(3X)-xx-2,2-xxxxxx

246-585-8

25057-89-0

Xxxx. 2

Xxxxx Xxx. 4

Eye Xxxxx. 2

Xxxx Xxxx. 1

H361d

H302

H319

H317

GHS08

GHS07

Wng

H361d

H302

H319

H317

orální: XXX&xxxx;= 1&xxxx;600 &xxxx;xx/xx XX“

„616-164-00-7

xxxxxxxxxxxxx (XXX); (2X)-2-{2-[(2,5-xxxxxxxxxxxxxx)xxxxxx]xxxxx}-2-(xxxxxxxxxxxx)-X-xxxxxxxxxxxxxx; (X)-2-(xxxxxxxxxxxx)-X-xxxxxx-2-[α-(2,5-xxxxxxxx)-x-xxxxx]xxxxxxxx

149961-52-4

Xxxx. 2

Xxxx. 2

Xxxxx Xxx. 4

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X351

X361x

X332

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X361x

X332

X410

xxxxxxxxx:

XXX&xxxx;= 1,3&xxxx;xx/x (xxxxx xxxx xxxx)

X&xxxx;= 100

X&xxxx;= 100“

x)

xxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx 615-007-00-X xx zrušuje.